| Name | Dexmedetomidine hydrochloride |
| Description | Dexmedetomidine hydrochloride (Precedex) is a potent, selective, orally active α2-adrenoceptor agonist with a Ki value of 1.08 nM. It shows 1620-fold selectivity over α1-adrenoceptors. Dexmedetomidine hydrochloride (Precedex) can protect against sepsis-induced acute lung injury through anti-inflammatory, anti-oxidative, and anti-apoptotic effects. |
| Kinase Assay | In vitro HDAC assay:HDAC activity is analyzed by using an HDAC assay kit. This assay is based on the ability of DU-145 nuclear extract, which is rich in HDAC activity, to mediate the deacetylation of the biotinylated [3H]-acetyl histone H4 peptide that is bound to streptavidin agarose beads. The release of [3H]-acetate into the supernatant is measured to calculate the HDAC activity. Sodium butyrate (0.25-1 mM) is used as a positive control. |
| In vitro | METHODS: NR8383 alveolar macrophages were stimulated with 10 μg/ml LPS for 24 hours and then treated with Dexmedetomidine hydrochloride (Precedex) (0.01, 0.1, 1, 10, 50 μM, 2 hours) for another 2 hours. CCK-8 assay was used to evaluate the effect of different concentrations of Dexmedetomidine hydrochloride (Precedex) pretreatment on the viability of LPS-treated NR8383 cells.
RESULTS Cell viability gradually increased with increasing concentrations of Dexmedetomidine hydrochloride (Precedex). [1] |
| In vivo | METHODS: Using C57BL/6J mice exposed to LPS, we investigated whether Dexmedetomidine hydrochloride (Precedex) (50 μg/kg, intraperitoneal injection) provides lung protection by regulating mitochondrial dynamics via the HIF-1a/HO-1 pathway in vivo.
RESULTS Dexmedetomidine hydrochloride (Precedex) alleviated lung pathological damage, reduced the oxidative stress index (OSI), improved mitochondrial dysfunction, upregulated the expression of HIF-1α and HO-1, and was accompanied by a shift in mitochondrial dynamics to fusion. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.45 mM), Sonication is recommended.
DMSO : 55 mg/mL (232.32 mM), Sonication is recommended.
H2O : 23.7 mg/mL (100.11 mM), Sonication is recommended.
|
| Keywords | α2-adrenoceptor | sedation | Medetomidine Hydrochloride | Inhibitor | inhibit | Dexmedetomidine hydrochloride | Dexmedetomidine Hydrochloride | Dexmedetomidine | Beta Receptor | anxiolysis | analgesia | adrenoceptor | AdrenergicReceptor | Adrenergic Receptor | (S)-Medetomidine | (+)-Medetomidine |
| Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Tolazoline hydrochloride | Phenylephrine hydrochloride | Amitriptyline hydrochloride | Isoprenaline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
